课件：首都医科大学北京地坛医院慢性丙型肝炎的抗病毒治疗.pptVIP

欢 迎 投 稿 ！ 010-8432 2006 010-8439 7196 Fax 1370 122 3262 Jun.cheng.ditan@ 欢 迎 投 稿 ！ 010-8432 2006 010-8439 7196 Fax 1370 122 3262 Jun.cheng.ditan@ 欢 迎 参 会 ！ 第四届地坛国际感染病学术会议 时间：2010年07月15-18日 地点：北京 语言：英语 010-8432 2006 010-8439 7196 Fax 1370 122 3262 Jun.cheng.ditan@ 谢 谢！ THANK YOU SUCCESS * * 可编辑 * Slide *. HCV Infection: Worldwide Prevalence “We stand at the precipice of a grave threat to our public health.…It affects people from all walks of life, in every state, in every country.” —C. Everett Koop, Former US Surgeon General.1 HCV infection is rapidly becoming a global epidemic and is one of the greatest public health threats faced by mankind. Although the incidence of HCV infection has declined in recent years, the sizable population of infected individuals continues to serve as a source of transmission to others, perpetuating the global impact of the disease. The demographic prevalence of HCV infection shown in this slide is based on published studies and/or data from 131 countries and regions as of June 1999 and does not necessarily reflect the prevalence of HCV infection today.2 According to information from the World Health Organization (WHO), nations with a prevalence exceeding 10% include Guinea (10.7%), Mongolia (10.7%), Burundi (11.1%), Bolivia (11.2%), Cameroon (12.5%), Rwanda (17.0%), and Egypt (18.1%).3 By World Health Organization (WHO) region, Africa has the highest prevalence of HCV infection (5.3%), compared with Eastern Mediterranean (4.6%), Western Pacific (3.9%), Southeast Asia (2.2%), the Americas (1.7%), and Europe (1.0%).4 ? 1. Koop CE. . 2. WHO. Wkly Epidemiol Rec. 2000;75:18-19. 3. WHO. Wkly Epidemiol Rec. 1999;74:421-428. 4. WHO. Hepatitis C. Fact sheet no. 164. * * Slide *. HCV治疗的结果：总体SVR 对于慢性丙型肝炎（CHC）感染的治疗，干扰素在抗病毒治疗中的疗效是一个显著的进步。 在一项1998年已经发表的研究中，单用alfa-2b干扰素治疗24或 48周显示治疗终止后（随访期末）24周的SVR分别为6%和13%1 相同的1998年的研究中，α- 2b干扰素3 MIU sc, tiw联合口服RBV 1000或1200mg/天的治疗获得的SVR为 38% (87/228) 1。在第二项由同一研究组(肝炎干预治疗组)1998年完成的该联合治疗48周后SVR